Literature DB >> 28371666

Angiopoietin-like protein 3 and 4 expression 4 and their serum levels in hepatocellular carcinoma.

Amal S El-Shal1, Haidy E Zidan2, Nearmeen M Rashad3, Fady M Wadea3.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is the 6th most common cancer and the 3rd leading cause of cancer causing death allover the world. The aim of this research to explore the clinical relevance of blood angiopoietin-like protein-3 (ANGPTL3) and ANGPTL4 expression and their proteins levels as non invasive biomarkers in cirrhotic and HCC patients and their influence on the clinicopathological features of HCC.
MATERIAL AND METHODS: This work comprised 200 patients with chronic hepatitis (120 cases complicated with cirrhosis, 80 patients with primary HCC) and 100 controls. circulating ANGPTL3 and ANGPTL4 expression was estimated by real-time polymerase chain reaction (RT-PCR). ANGPTL3 and ANGPTL4 protein levels were determined by enzyme-linked immunosorbent assay (ELISA).
RESULTS: The circulating ANGPTL3 and ANGPTL 4 expression was significantly elevated in HCC cases compared to chronic hepatitis patients and controls. There were much more serum ANGPTL3 and ANGPTL4 values in HCC and chronic hepatitis patients as compared to controls, but we couldn't detect this significance between chronic hepatitis and HCC cases as regards ANGPTL4. By Multiple stepwise linear regression analysis, an increased ANGPTL3 expression, alpha-fetoprotein (AFP), serum ANGPTL 3 levels, Child-Pugh grade were significantly assosciatedassociated with increased risk of HCC. Logistic regression analysis revealed that ANGPTL 3 expression and AFP levels were the only pridectorspredictors of HCC (odd's ratio (OR)=8.9; 8.6 respectively, P=0.003). Receiver operator characteristic (ROC) demonsterated that serum ANGPTL3 and ANGPTL4 levels were usufuluseful biomarkers discriminating chronic hepatitis cases from controls (AUC=0.820,0.887, respectively P<0.001). However, they fail to discriminate HCC patients from chronic hepatitis patients (P=0.27,0.12 respectively). Moreover, ANGPTL3 and ANGPTL 4 expression were promising biomarkers discriminating chronic hepatitis cases from controls and those HCC cases from chronic hepatitis patients (P<0.001). Combined ANGPTL3 expression and serum level wasn't useful in discriminating HCC patient from chronic hepatitis (P=0.09). In contrast, combined ANGPTL4 expression and serum level was an useful biomarker discriminating HCC cases from chronic hepatitis.
CONCLUSION: ANGPTL3 and ANGPTL 4 expression and serum levels can be promising non invasive biomarkers in diagnosis of chronic hepatitis and HCC especially their expression could be useful in discriminating HCC from chronic hepatitis patients.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiopoietin-like protein-3; Angiopoietin-like protein-4; Chronic hepatitis; Cirrhosis; Hepatocellular carcinoma; Real-time polymerase chain reaction

Mesh:

Substances:

Year:  2017        PMID: 28371666     DOI: 10.1016/j.cyto.2017.03.006

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  15 in total

1.  Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity.

Authors:  Sylvia S W Ng; Hong Zhang; Lisa Wang; Deborah Citrin; Laura A Dawson
Journal:  NPJ Precis Oncol       Date:  2020-07-14

2.  Angiopoietin-like 4 binds neuropilins and cooperates with VEGF to induce diabetic macular edema.

Authors:  Akrit Sodhi; Tao Ma; Deepak Menon; Monika Deshpande; Kathleen Jee; Aumreetam Dinabandhu; Jordan Vancel; Daoyuan Lu; Silvia Montaner
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

3.  Angiopoietin-like-3 knockout protects against glomerulosclerosis in murine adriamycin-induced nephropathy by attenuating podocyte loss.

Authors:  Rufeng Dai; Haimei Liu; Xinli Han; Junchao Liu; Yihui Zhai; Jia Rao; Qian Shen; Hong Xu
Journal:  BMC Nephrol       Date:  2019-05-24       Impact factor: 2.388

Review 4.  The Prospect and Challenges to the Flow of Liquid Biopsy in Africa.

Authors:  Dada Oluwaseyi Temilola; Martha Wium; Tangbadioa Herve Coulidiati; Henry Ademola Adeola; Giuseppina Maria Carbone; Carlo Vittorio Catapano; Luiz Fernando Zerbini
Journal:  Cells       Date:  2019-08-09       Impact factor: 6.600

5.  ANGPTL3 Overexpression Suppresses the Development of Oncogenic Properties in Renal Cell Carcinoma via the Wnt/β-Catenin Signaling Pathway and Predicts Good Prognosis.

Authors:  Yu-Jian Zhang; Lin Zhang; Fei Feng; Qi-Feng Cao
Journal:  Dis Markers       Date:  2021-08-24       Impact factor: 3.434

Review 6.  New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.

Authors:  Xin Su; Dao-Quan Peng
Journal:  Lipids Health Dis       Date:  2018-01-15       Impact factor: 3.876

Review 7.  Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer.

Authors:  Carmine Carbone; Geny Piro; Valeria Merz; Francesca Simionato; Raffaela Santoro; Camilla Zecchetto; Giampaolo Tortora; Davide Melisi
Journal:  Int J Mol Sci       Date:  2018-02-01       Impact factor: 5.923

8.  Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity.

Authors:  Sylvia S W Ng; Hong Zhang; Lisa Wang; Deborah Citrin; Laura A Dawson
Journal:  NPJ Precis Oncol       Date:  2020-07-14

Review 9.  A review of the multifunctionality of angiopoietin-like 4 in eye disease.

Authors:  Xinyue Yang; Yan Cheng; Guanfang Su
Journal:  Biosci Rep       Date:  2018-09-13       Impact factor: 3.840

10.  Association between ANGPTL-4 and the proinflammatory process in cancer cachexia patients.

Authors:  Nelson Inácio Pinto Neto; Valter Tadeu Boldarine; Ana Claudia Losinskas Hachul; Lila Missae Oyama; Joanna Darck Carola Correia Lima; Estefania Simoes Fernandez; José Pinhata Otoch; Paulo Sérgio Martins de Alcântara; Flavio Tokeshi; Marilia Cerqueira Leite Seelaender; Claudia Maria da Penha Oller do Nascimento
Journal:  Oncotarget       Date:  2019-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.